Is Highly Sensitive Troponin better than Sensitive Troponin in women?
Research type
Research Study
Full title
A study to determine whether Highly Sensitive Troponin will identify patients, especially a large proportion of women, at a higher cardiovascular risk who would have otherwise tested negative using the current assay.
IRAS ID
144746
Contact name
Marta Lapsley
Contact email
Sponsor organisation
Epsom and St Helier University Hospitals NHS Trust
Clinicaltrials.gov Identifier
N/A, N/A
Research summary
I would like to do my MSc project comparing Highly Sensitive Troponin (HST) marker against the current Sensitive Troponin (ST) marker.
From reading various recent publications and studies conducted at the University of Edinburgh, HST is believed to be a very sensitive cardiac marker, detecting lower levels of troponin released into the blood than that of the current ST. Patients with small rises in troponin are known to be at risk of suffering a more major cardiac event, including myocardial infarction (heart attack)later in life.
This new marker is especially beneficial to women as they have a much lower level of troponin released after a myocardial damage (heart damage) than men. Hence, HST will identify patients, possibly a larger proportion of women who will otherwise have tested negative to be at a higher risk of cardiovascular disease/complications. Detection of a smaller rise will also allow earlier identification of a developing myocardial infarction.
Identifying those at risk at an early stage before a ‘full blown’ myocardial infarction or stoke, should allow for better preventative treatment, potentially saving many lives, taking pressure of A/E and saving money in the NHS, as patients do not need to wait as long;current assay require patients to wait six hours, however, with the new assay the wait time is only three hours.
HST will be measured on negative samples with a few for positive confirmation in parallel with standard troponin assay. Followed by analysis on previously negative female samples. The age, relevant clinical details such as chest pains, heart disease, renal/kidney impairment and thyroid disease etc will be recorded prior to anonymization to see if there is a correlation on positive samples identified.Furthermore there will be a kit evaluation on the ARCHITECT I-module. Once these parameters are established, then only the study will be carried out.
REC name
London - Brent Research Ethics Committee
REC reference
14/LO/1155
Date of REC Opinion
10 Jul 2014
REC opinion
Favourable Opinion